HK1069179A1 - Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments - Google Patents

Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments

Info

Publication number
HK1069179A1
HK1069179A1 HK05102425.6A HK05102425A HK1069179A1 HK 1069179 A1 HK1069179 A1 HK 1069179A1 HK 05102425 A HK05102425 A HK 05102425A HK 1069179 A1 HK1069179 A1 HK 1069179A1
Authority
HK
Hong Kong
Prior art keywords
peptidomimetics
nucleic acid
peptides
treatments
acid damaging
Prior art date
Application number
HK05102425.6A
Other languages
English (en)
Inventor
Takumi Kawabe
Hidetaka Kobayashi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of HK1069179A1 publication Critical patent/HK1069179A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK05102425.6A 2002-01-17 2005-03-21 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments HK1069179A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35020802P 2002-01-17 2002-01-17
PCT/IB2003/000425 WO2003059942A2 (en) 2002-01-17 2003-01-17 Peptides and peptidomimetics having anti-proliferative activity and their use

Publications (1)

Publication Number Publication Date
HK1069179A1 true HK1069179A1 (en) 2005-05-13

Family

ID=23375680

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05102425.6A HK1069179A1 (en) 2002-01-17 2005-03-21 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments

Country Status (19)

Country Link
US (3) US6995135B2 (ja)
EP (1) EP1483290B1 (ja)
JP (3) JP4041066B2 (ja)
KR (2) KR101103412B1 (ja)
CN (2) CN101092455B (ja)
AT (1) ATE404584T1 (ja)
AU (2) AU2003235576C1 (ja)
CA (1) CA2471192C (ja)
CY (1) CY1108470T1 (ja)
DE (1) DE60322845D1 (ja)
DK (1) DK1483290T3 (ja)
ES (1) ES2311703T3 (ja)
HK (1) HK1069179A1 (ja)
IL (2) IL162836A0 (ja)
NO (1) NO332461B1 (ja)
PT (1) PT1483290E (ja)
SI (1) SI1483290T1 (ja)
WO (1) WO2003059942A2 (ja)
ZA (1) ZA200405455B (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1483290T1 (sl) * 2002-01-17 2009-02-28 Takeda Pharmaceutical Peptidi in peptidomimetiki, ki imajo antiproliferacijsko aktivnost in/ali okrepijo sredstva ali obdelave, ki poškodujejo nukleinsko kislino
ATE520653T1 (de) * 2002-06-06 2011-09-15 Canbas Co Ltd Verbindungen, die den durch dna-schädigung induzierten g2-checkpoint des zellzyklus stilllegen und/oder die antikrebswirkung von dna- schädigenden behandlungen erhöhen
US20040109853A1 (en) * 2002-09-09 2004-06-10 Reactive Surfaces, Ltd. Biological active coating components, coatings, and coated surfaces
US20100233146A1 (en) * 2002-09-09 2010-09-16 Reactive Surfaces, Ltd. Coatings and Surface Treatments Having Active Enzymes and Peptides
US20100210745A1 (en) * 2002-09-09 2010-08-19 Reactive Surfaces, Ltd. Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes
US20050058689A1 (en) * 2003-07-03 2005-03-17 Reactive Surfaces, Ltd. Antifungal paints and coatings
US20090238811A1 (en) * 2002-09-09 2009-09-24 Mcdaniel C Steven Enzymatic Antimicrobial and Antifouling Coatings and Polymeric Materials
US20110070376A1 (en) * 2002-09-09 2011-03-24 Reactive Surfaces, Ltd. Anti-fouling Paints & Coatings
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
CN1812805A (zh) * 2003-06-25 2006-08-02 坎巴斯有限公司 具有免疫调节活性、抗炎活性和抗病毒活性的肽和肽模仿物
US8618066B1 (en) 2003-07-03 2013-12-31 Reactive Surfaces, Ltd., Llp Coating compositions having peptidic antimicrobial additives and antimicrobial additives of other configurations
JP2007501608A (ja) * 2003-08-08 2007-02-01 株式会社 キャンバス 抗癌治療の効力を推定するための感受性試験
US20060286006A1 (en) * 2005-06-21 2006-12-21 Mcdaniel C S Method and apparatus for the treatment of fluid waste streams
AU2007306927B2 (en) * 2006-10-11 2013-10-03 Aushealth Corporate Pty Ltd The use of a DNA damaging agent and a ligand for the treatment of cancer
US8629650B2 (en) * 2008-05-13 2014-01-14 Qualcomm Incorporated Wireless power transfer using multiple transmit antennas
US20100112089A1 (en) * 2008-05-14 2010-05-06 Takeda Pharmaceutical Company Limited Peptide compound and use thereof
US8388904B1 (en) 2008-12-22 2013-03-05 Reactive Surfaces, Ltd., Llp Equipment decontamination system and method
FR2942798B1 (fr) * 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
US20130123196A1 (en) * 2011-08-31 2013-05-16 New York University Thioether-, ether-, and alkylamine-linked hydrogen bond surrogate peptidomimetics
RU2732440C2 (ru) * 2013-06-24 2020-09-16 Кэнбас Ко., Лтд. Пептиды и пептидомиметики для комбинированного применения и лечения в субпопуляциях пациентов с раковыми заболеваниями
CN113861268A (zh) * 2014-05-21 2021-12-31 恩特拉达治疗学股份有限公司 细胞穿透肽及其制备和使用方法
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
WO2016033368A1 (en) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
TWI805542B (zh) * 2015-10-23 2023-06-21 日商坎巴斯有限公司 用於癌症治療之肽及擬肽與t細胞活化劑及/或查核點抑制劑之組合
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
US11576946B2 (en) 2018-01-29 2023-02-14 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-NFAT interaction
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
WO2019217682A1 (en) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
CN114989254B (zh) * 2022-06-17 2023-11-03 中山大学 一种多肽及其设计方法和在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2385257A1 (en) * 1999-09-22 2001-03-29 Canbas Co., Ltd. Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
WO2001094411A1 (en) 2000-06-05 2001-12-13 The Regents Of The University Of California Peptides modulating protease activated receptors and methods of using same
SI1483290T1 (sl) * 2002-01-17 2009-02-28 Takeda Pharmaceutical Peptidi in peptidomimetiki, ki imajo antiproliferacijsko aktivnost in/ali okrepijo sredstva ali obdelave, ki poškodujejo nukleinsko kislino

Also Published As

Publication number Publication date
JP4041066B2 (ja) 2008-01-30
NO332461B1 (no) 2012-09-24
AU2003235576A1 (en) 2003-07-30
EP1483290B1 (en) 2008-08-13
JP2011037896A (ja) 2011-02-24
CN101092455B (zh) 2012-07-04
CA2471192C (en) 2014-05-20
AU2003235576B2 (en) 2009-01-29
WO2003059942A2 (en) 2003-07-24
JP4873646B2 (ja) 2012-02-08
CN100360564C (zh) 2008-01-09
US20090253635A1 (en) 2009-10-08
US20060084610A1 (en) 2006-04-20
KR100863090B1 (ko) 2008-10-13
PT1483290E (pt) 2008-09-19
JP2005529845A (ja) 2005-10-06
WO2003059942A9 (en) 2003-11-27
DK1483290T3 (da) 2008-11-03
ATE404584T1 (de) 2008-08-15
CN101092455A (zh) 2007-12-26
US7476657B2 (en) 2009-01-13
JP2008044946A (ja) 2008-02-28
AU2009201711A1 (en) 2009-05-21
CA2471192A1 (en) 2003-07-24
CY1108470T1 (el) 2014-04-09
US20040248783A1 (en) 2004-12-09
CN1642978A (zh) 2005-07-20
US6995135B2 (en) 2006-02-07
EP1483290A2 (en) 2004-12-08
WO2003059942A3 (en) 2004-10-07
IL162836A0 (en) 2005-11-20
ZA200405455B (en) 2005-08-31
KR20040081750A (ko) 2004-09-22
ES2311703T3 (es) 2009-02-16
KR101103412B1 (ko) 2012-01-06
SI1483290T1 (sl) 2009-02-28
IL162836A (en) 2011-09-27
KR20080006649A (ko) 2008-01-16
DE60322845D1 (de) 2008-09-25
NO20043381L (no) 2004-10-12
AU2009201711B2 (en) 2011-12-15
AU2003235576C1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
HK1069179A1 (en) Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments
MY182232A (en) Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations
PT1955700E (pt) Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
TW200502385A (en) Modulation of forkhead box o1a expression
PT1796660T (pt) Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta
GB0223038D0 (en) Therapeutic compounds
MXPA05009694A (es) Metodos para mejorar la calidad de la piel.
GB9903762D0 (en) Organic compounds
RS20060073A (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
MY140132A (en) Thiazolidin-4-one derivatives for use in the treatment of anemias
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BR9808221A (pt) Método de tratamento de tumor.
YU11402A (sh) Nova primena docetaksela za lečenje hepatoma
EP1407752A4 (en) COMPOSITE POWDERS AND SKIN PREPARATIONS FOR EXTERNAL USE CONTAINING THESE POWDERS
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
WO2005062958A3 (en) Meth0ds of using hcn genes to treat cardiac arrhythmias
ATE243522T1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
MXPA05004133A (es) Nuevos compuestos antitumorales.
WO2005094282A3 (en) Combination therapy comprising cloretazinetm
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition
HK1082261A1 (en) 4-methylhexanoic kahalalide f compound
WO2000074667A3 (en) Compositions active in telomere damage comprising a taxane and telomerase inhibitor
DE602004012759D1 (de) Behandlung von fibrosen

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230116